Your browser doesn't support javascript.
loading
Applications of covalent chemistry in targeted protein degradation.
Lu, Dong; Yu, Xin; Lin, Hanfeng; Cheng, Ran; Monroy, Erika Y; Qi, Xiaoli; Wang, Meng C; Wang, Jin.
Afiliação
  • Lu D; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston TX 77030, USA. wangj@bcm.edu.
  • Yu X; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston TX 77030, USA. wangj@bcm.edu.
  • Lin H; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston TX 77030, USA. wangj@bcm.edu.
  • Cheng R; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston TX 77030, USA. wangj@bcm.edu.
  • Monroy EY; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston TX 77030, USA. wangj@bcm.edu.
  • Qi X; Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston TX 77030, USA. wangj@bcm.edu.
  • Wang MC; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston TX 77030, USA.
  • Wang J; Huffington Center on Aging, Baylor College of Medicine, Houston TX 77030, USA.
Chem Soc Rev ; 51(22): 9243-9261, 2022 Nov 14.
Article em En | MEDLINE | ID: mdl-36285735
Proteolysis-targeting chimeras (PROTACs) and targeted covalent inhibitors (TCIs) are currently two exciting strategies in the fields of chemical biology and drug discovery. Extensive research in these two fields has been conducted, and significant progress in these fields has resulted in many clinical candidates, some of which have been approved by FDA. Recently, a novel concept termed covalent PROTACs that combine these two strategies has emerged and gained an increasing interest in the past several years. Herein, we briefly review and highlight the mechanism and advantages of TCIs and PROTACs, respectively, and the recent development of covalent PROTACs using irreversible and reversible covalent chemistry.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ubiquitina-Proteína Ligases / Descoberta de Drogas Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ubiquitina-Proteína Ligases / Descoberta de Drogas Idioma: En Ano de publicação: 2022 Tipo de documento: Article